

AMENDMENTS TO THE CLAIMS

Claims 1-7 (canceled).

Claim 8 (currently amended) A method of inhibiting cell-cell interaction, comprising:

contacting the cells with an antibody directed against a peptide with a sequence of SEQ ID No. 41 or with a sequence of SEQ ID No. 2 that is derived from a cell surface vascular endothelial growth factor and type I collagen inducible protein (VCIP), wherein said contact with the antibody blocks the step of blocking the binding of integrins to the cell surface vascular endothelial growth factor and type I collagen inducible protein (VCIP), thereby inhibiting the cell-cell interaction.

Claim 9 (original) The method of claim 8, wherein said cell-cell interaction is mediated by integrin ligand.

Claims 10-13 (canceled)

Claim 14 (currently amended) The method of claim 8, wherein said cell-cell interaction contributes to ~~a biological process selected from the group consisting of normal cell cycle progression, unwanted cell cycle progression,~~

~~vascular malformation, expansion of atherosclerotic lesions, invasion of tumor cells, inflammation, cell motility and angiogenesis~~ or a combination thereof.

Claim 15 (currently amended) A method of treating a patient ~~having with~~ a pathological condition ~~resulted~~ caused by ~~from~~ integrin-mediated cell-cell interaction, comprising:

~~said method comprises the step of~~ administering to said patient an agent antibody directed against a peptide with a sequence of SEQ ID No. 41 or SEQ ID No. 2 that is derived from a cell surface vascular endothelial growth factor and type I collagen inducible protein (VCIP), wherein said antibody blocks the binding of integrin to the cell surface vascular endothelial growth factor and type I collagen inducible protein (VCIP), thereby treating the patient with the pathological condition caused by the integrin-mediated cell-cell interaction.

Claims 16-19 (canceled)

Claim 20 (currently amended) The method of claim 15, wherein said cell-cell interaction contributes to ~~a biological process selected from the group consisting of normal cell cycle progression, unwanted cell cycle progression, vascular malformation, expansion of atherosclerotic lesions, invasion of tumor cells, inflammation, cell motility and angiogenesis,~~ or a combination thereof.

Claim 21 (currently amended) The method of claim 15, wherein said pathological condition is ~~selected from the group consisting of stroke, thrombosis, tumor growth, metastasis, arthritis, cardiac infarction, psoriasis, diabetic retinopathy, inflammation, and angiogenesis~~ or a combination thereof.

Claims 22-31 (canceled).

Claim 32 (currently amended) A method of inhibiting angiogenesis and the formation of capillaries in a patient in need of such a treatment, comprising:

~~the step of~~ administering to said patient a pharmacologically effective amount of antibody directed against a peptide with a sequence of SEQ ID No. 41 or SEQ ID No. 2 that is derived from vascular endothelial growth factor and type I collagen inducible protein (VCIP), wherein said ~~peptide comprises a RGD sequence~~ antibody inhibits integrin-mediated cell-cell interaction, thereby inhibiting angiogenesis and the formation of capillaries in ~~[[a]]~~ the patient in need of such a treatment .

Claims 33-41 (canceled).